1999

November

• William Raub, Ph.D., November 9, 1999
  Deputy Assistant Secretary for Science Policy, Department of Health and Human Services before the Subcommittee on National Security, Veterans' Affairs, discuss Federal policies governing the administration of investigational new drugs to U.S. military personnel, including the safeguards and protections recently announced in the Executive Order 13139 issued by the President.

October

• William K. Hubbard, October 28, 1999
  Senior Associate Commissioner for Policy, Planning and Legislation, Food and Drug Administration before the Subcommittee on Oversight and Investigations Committee on Veterans' Affairs, to provide an update on FDA's efforts to validate our optimism as the year 2000 draws near.
• William K. Hubbard, October 21, 1999
  Senior Associate Commissioner for Policy, Planning and Legislation, Food and Drug Administration before the House Committee on Commerce Subcommittee on Health and Environment, to provide an update on the Year 2000 (Y2K) date issue as it relates to medical devices, drugs and biologics.
• Jane E. Henney, M.D.,October 21, 1999
  Commissioner of Food and Drugs of the Food and Drug Administration before the Committee on Health, Education, Labor and Pensions, on the Agency's progress on its implementation of the Food and Drug Administration Modernization Act of 1997 (FDAMA or Modernization Act).
• James H. Maryanski Ph.D.,October 19, 1999
  Biotechnology Coordinator, CFSAN of Food and Drug Administration before the Committee on Science Subcommitee in Basic ResearchForestry, on regulatory program for foods derived from new plant varieties, including genetically engineered varieties.
• Kathryn C. Zoon, Ph.D.,October 12, 1999
  Director, Center for Biologics Evaluation and Research of the Food and Drug Administration before the Committee on Government Reform to discuss vaccine licensing generally, and specifically, the safety and efficacy of the anthrax vaccine.
• James H. Maryanski Ph.D.,October 7, 1999
  Biotechnology Coordinator, CFSAN of Food and Drug Administration before the Senate Committee on Agriculture, Nurition and Forestry, on regulatory program for foods derived from new plant varieties, including genetically engineered varieties.

September

• Jane Henney, M.D., August 4, 1999
  Commissioner of Food and Drug Administration before the Senate Governmental Affairs Committee, on behalf of the President's Council of Food Safety.

July

• Jane Woodcock, M.D., July 30, 1999
  Director, Center for Drug Evaluation and Research of the Food and Drug Administration before the Subcommittee on Oversight and Investigations, on the benefits and risks of pharmaceutical sales over the Internet.
• Susan S. Ellenberg, Ph.D., July 21, 1999
  Director, Division of Biostatistics and Epidemiology,CBER of the Food and Drug Administration before the subcommittee on National Security, Veterans Affairs and International Relations, FDA's Vaccine Adverse Event Reporting System (VAERS) and its interface with the Department of Defense's (DOD) Anthrax Vaccine Immunization Program (AVIP).
• Morris E. Potter, July 1, 1999
  Director of Food Safety Initiatives,CFSAN of the Food and Drug Administration before the subcommittee on Government Management, Restructuring, and the District of Columbia to testify on the Federal role in the oversight of egg safety and the related General Accounting Office's (GAO) report.

May

• Joseph A. Levitt, May 27, 1999
  Director, Center for Food Safety and Applied Nutrition of the Food and Drug Administration before the Committee on Government Reform to discuss FDA's adverse event reporting systems, particularly the system for monitoring special nutritional products, including dietary supplements.
• William K. Hubbard, May 25, 1999
  Acting Deputy Commissioner for Policy of the Food and Drug Administration before the Subcommittee on Oversight and Investigation, to provide information on the Year 2000 date issue as it relates to medical devices.
• Susan S. Ellenberg, Ph.D., May 18, 1999
  Director, Biostatistics & Epidemiology Division, CBER of the Food and Drug Administration before the Subcommittee on Criminal Justice, Drug Policy and Human Resources, to discuss the Vaccine Adverse Event Reporting System (VAERS), designed to receive and evaluate reports of adverse events following vaccinations.

April

• Kathryn C. Zoon, Ph.D., April 29, 1999
  Director, Center for Biologics Evaluation and Research of the Food and Drug Administration before the Subcommittee on National Security, Veterans Affair and International Relations, to discuss the safety and efficacy of the anthrax vaccine.
• Thomas Shope, M.D., April 20, 1999
  Special Assistant to the Director, Office of Science and Technology, Center for Devices and Radiological Health of the Food and Drug Administration before the Committee on Veterans' Affairs, to provide information on the Year 2000 date issue as it relates to medical devices.
• William K. Hubbard, April 15, 1999
  Acting Deputy Commissioner for Policy of the Food and Drug Administration before the Subcommittee on Oversight and Investigation, to provide information on the Year 2000 date issue as it relates to medical devices and pharmaceuticals.

March

• Jane Henney, M.D., March 25, 1999
  Commissioner of Food and Drug Administration before the Committee of Government Reform, to discuss of implementation of the Dietary Supplement Health and Education Act (DSHEA) of 1994.
• Elizabeth D. Jacobson, Ph.D., March 25, 1999
  Acting Director Center for Devices and Radiological Health of the Food and Drug Administration before the Committee on Education and the Workforce, to discuss issues related to the regulation of natural rubber latex gloves.
• Jane Henney, M.D., March 16, 1999
  Commissioner of Food and Drug Administration before the Committee on Appropriations, to discuss the highlights of the Agency's food safety accomplishments for fiscal 1998, the plans for fiscal year 1999 and the expectations for food safety with the proposed budget for fiscal year 2000.
• Nicholas Reuter, MPH, March 11, 1999
  Associate Director for Domestic and International Drug Control, Office of Health Affairs before the Subcommittee on Oversight and Invetigations Committee on Commerce, testified on the role of the Food and Drug Administration (FDA or Agency) in the scheduling of drugs under the Controlled Substances Act (CSA), 21 U.S.C. § 811.